Table 1.

Expression of WT1 RNA, HLA-A0201 expression and ESK1 binding^*

Cancer cell	HLA-A2 expression	WT1 mRNA or protein**	ESK1 binding	Binding Ratio: BB7.2 to isotype IgG
Solid tumor cell lines
JMN	Positive	+	Positive	248
Meso 37	Positive	+	Positive	68
Meso 47	Positive	+	Positive	17
H2452	Positive	+	Positive	20
Meso34	Positive	+	Positive	37
Meso-56	Positive	+	Positive	23
H2373	Positive	+	Negative	1.6
MSTO	Negative	+	Negative	1.4
VAMT	Negative	+	Negative	NT
SKOV3	Positive	+**	Positive	14.7
OVCAR3	Positive	+**	Positive	> 20
CC-228	Positive	+**	Positive	> 20
RMS-13	Positive	+**	Positive	> 20
Leukemias and Hematopoietic cells
BV173	Positive	+	Positive	196
BA25	Positive	+	Positive	118
ALL-3	Positive	+	Positive	60
U266	Positive	+	Negative	1.8
697	Positive	+	Negative	4.1
LAMA	Positive	+	Negative	6
SKLY-16	Positive	−	Negative	1.9
HL-60	Negative	+	Negative	0.4
K562	Negative	+	Negative	1.5
B-Jab	Positive	−	Negative	11
T2	Positive	−	Negative	>20
Fresh AML cells (n=4)	Positive	NT	2 positive; 2 weakly positive	N/A
Fresh AML cells (n=8)	Negative	NT	Negative	N/A
Healthy CD3+ cells (n=9)	Positive	NT	Negative	N/A
Healthy CD33+ cells (n=9)	Positive	NT	Negative	N/A
Healthy CD19+ cells (n=9)	Positive	NT	2 weakly positive	N/A
Healthy CD3+ cells (n=7)	Negative	NT	Negative	1–3
Healthy CD33+ cells (n=7)	Negative	NT	Negative	1–3
Healthy CD19+ cells (n=7)	Negative	NT	Negative	1–3

^*HLA-A2 is by genotype. WT1 mRNA expression level was estimated according to our previous study (29), in which WT1 levels are shown as fold increase in WT1 expression level relative to that expressed in K562 cells.

^**In four lines Western blot was done instead of PCR. ESK1 binding and BB7.2 (cell surface HLA-A02) were measured by flow cytometry.

NT= not tested. N/A= not applicable.